Effectiveness of Enhanced Terminal Room Disinfection to Prevent Healthcare-associated Infections (HAIs)

Not Applicable

Completed

• Conditions: Multidrug Resistant Organisms; Healthcare Associated Infections
• Interventions: Other: Bleach; Other: Quaternary ammonium; Other: Quaternary ammonium and UV-C light; Other: Bleach and UV-C light

• Registration Number: NCT01579370
• Lead Sponsor: Duke University

Brief Summary

Enhanced terminal room disinfection is a novel, promising, but still unproven strategy for the prevention of healthcare-associated infections (HAIs) due to selected multidrug-resistant (MDR) bacterial pathogens. The investigators will perform a large prospective, multicenter study enhanced terminal room disinfection to 1) determine the efficacy and feasibility of enhanced terminal room disinfection strategies to prevent HAIs and 2) determine the impact of environmental contamination on acquisition of MDR-pathogens among hospitalized patients.

Detailed Description

Meticulous and consistent use of hand hygiene before and after patient care remains the cornerstone of infection prevention in all health care settings. However, clean hands are not sufficient to prevent all healthcare-associated infections (HAIs), as 1) hands of healthcare workers easily become contaminated from contact with contaminated environmental surfaces in patient rooms after appropriate hand hygiene has been performed and before direct patient care and 2) direct contact by patients with preexisting contaminated environmental surfaces in their hospital rooms can lead to colonization or infection. Thus, novel strategies are needed to prevent HAIs, particularly those caused by multidrug-resistant (MDR) pathogens that persist in the environment such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci (VRE), Clostridium difficile, and Acinetobacter.

Enhanced environmental disinfection methods may lead to reduced risk of exposure to or acquisition of HAIs and MDR-pathogens and overcome a critical issue facing healthcare today - hospitals rooms are often poorly cleaned and disinfected. Enhanced terminal room disinfection strategies using bleach and/or UV-C emitting devices have been investigated only in experimental conditions; the efficacy, effectiveness, and feasibility of enhanced terminal room disinfection to prevent HAIs are unknown. Thus, the scientific evidence for such interventions currently is insufficient for their inclusion in evidence-based guidelines.

This study will investigate the hypothesis that enhanced terminal room disinfection protocols (using chlorine-based cleaning agents with or without UV-C light-emitting devices) will decrease the overall risk of HAIs in the hospital and, more specifically, in subsequent patients who are cared for in the same room. This prospective investigation will employ a crossover design utilizing four room cleaning/disinfection protocols in 9 hospitals, including 2 tertiary care, 1 VA, and 6 community hospitals. Phase T2 data from this study will be useful in assessing the clinical efficacy and feasibility of individual disinfection strategies. Thus, the goals of the investigators proposed research are to 1) determine the efficacy and feasibility of enhanced terminal room disinfection strategies to prevent HAIs and 2) determine the impact of environmental contamination on acquisition of MDR-pathogens among hospitalized patients.

Study Timeline

• Study Start: 2012-04
• Study First Submitted: 2012-04-05
• Study First Submitted QC: 2012-04-16
• Study First Posted: 2012-04-18
• Primary Completion: 2014-07
• Study Completion: 2015-08
• Status Verified: 2015-11
• Last Update Submitted: 2015-11-15
• Last Update Posted: 2015-11-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21395

Inclusion Criteria

• Any seed room (ie., room from which a patient with one of the target organisms has been transferred or discharged)

Read More

Exclusion Criteria

• None, intervention is at level of the room, not the patient
• Patient outcomes will be excluded if clinical cultures are obtained within 48 hours of admission to the room of interest.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
Bleach	Bleach	Rooms will be terminally cleaned using bleach-containing products.
Quaternary ammonium	Quaternary ammonium	Rooms will be terminally cleaned using quaternary ammonium-containing compounds, the reference standard for hospital cleaning in US hospitals.
Quaternary ammonium and UV-C light	Quaternary ammonium and UV-C light	Rooms will be terminally cleaned with quaternary ammonium-containing solutions followed by irradiation by a UV-C light emitting device.
Bleach and UV-C light	Bleach and UV-C light	Rooms will be terminally cleaned with bleach-containing solutions followed by irradiation by a UV-C light emitting device.

Primary Outcome Measures

Name	Time	Method
Clinical incidence rate of four target organisms among patients admitted to a study room	90 days	Patients will be monitored for clinical cultures that grow one of four target organisms (MRSA, VRE, C. difficile, and MDR-Acinetobacter) following admission to a "seed" room. Cultures for vegetative bacteria (MRSA, VRE, Acinetobacter) will be included if obtained within 90 days of discharge from a seed room; cultures for C. difficile will be included if they are obtained within 28 days of discharge from a seed room.
Clinical incidence rate of C. difficile among patients admitted to a study room	28 days	Patients will be monitored for clinical cultures that grow C. difficile following admission to a "seed" room.

Secondary Outcome Measures

Name	Time	Method
Clinical incidence rate of C. difficile among all patients admitted to the hospital	28 days	All hospitalized patients will be monitored for clinical cultures that grow C. difficile regardless of exposure to seed room.
Incidence rate of healthcare-associated infections caused by target bacteria (MRSA, VRE, C. difficile, and MDR-Acinetobacter) among patients admitted to a seed room.	Patients will be followed an average of 30 days	Patients will be monitored for HAIs due to one of four target organisms (MRSA, VRE, C. difficile, and MDR-Acinetobacter) following admission to a "seed" room. NHSN definitions for HAIs will be used.
Incidence rate of healthcare-associated infections caused by MDR-Acinetobacter among patients admitted to a seed room.	Patients will be followed an average of 30 days	Patients will be monitored for HAIs due to MDR-Acinetobacter following admission to a "seed" room. NHSN definitions for HAIs will be used.
Incidence rate of healthcare-associated infections caused by MDR-Acinetobacter among all hospitalized patients.	Patients will be followed an average of 30 days	Patients will be monitored for HAIs due to MDR-Acinetobacter, regardless of exposure to seed room. NHSN definitions for HAIs will be used.
Clinical incidence rate of target vegetative bacteria (MRSA, VRE, Acinetobacter) among patients admitted to a seed room.	90 days	Patients will be monitored for clinical cultures that grow one of three target vegetative organisms (MRSA, VRE, and MDR-Acinetobacter) following admission to a "seed" room.
Clinical incidence rate of target organisms among all patients admitted to the hospital	90 days	All hospitalized patients will be monitored for clinical cultures that grow one of four target organisms (MRSA, VRE, C. difficile, and MDR-Acinetobacter) regardless of exposure to seed room.
Incidence rate of healthcare-associated infections caused by VRE among patients admitted to a seed room.	Patients will be followed an average of 30 days	Patients will be monitored for HAIs due to VRE following admission to a "seed" room. NHSN definitions for HAIs will be used.
Incidence rate of healthcare-associated infections caused by MRSA among all hospitalized patients.	Patients will be followed an average of 30 days	Patients will be monitored for HAIs due to MRSA, regardless of exposure to seed room. NHSN definitions for HAIs will be used.
Clinical incidence rate of MRSA among all patients admitted to the hospital	90 days	All hospitalized patients will be monitored for clinical cultures that grow MRSA regardless of exposure to seed room.
Clinical incidence rate of VRE among all patients admitted to the hospital	90 days	All hospitalized patients will be monitored for clinical cultures that grow VRE regardless of exposure to seed room.
Clinical incidence rate of MDR-Acinetobacter among all patients admitted to the hospital	90 days	All hospitalized patients will be monitored for clinical cultures that grow MDR-Acinetobacter regardless of exposure to seed room.
Incidence rate of healthcare-associated infections caused by MRSA among patients admitted to a seed room.	Patients will be followed an average of 30 days	Patients will be monitored for HAIs due to MRSA following admission to a "seed" room. NHSN definitions for HAIs will be used.
Incidence rate of healthcare-associated infections caused by VRE among all hospitalized patients.	Patients will be followed an average of 30 days	Patients will be monitored for HAIs due to VRE, regardless of exposure to seed room. NHSN definitions for HAIs will be used.
Missed Opportunities	each study period (6 months)	Use of UV-C emitting devices will be monitored and "missed opportunities" (ie, UV-C emitter should have been used per protocol and was not) will be tracked and summarized. This proportion will be calculated for each study arm, each of which lasts 6 months. The "quaternary ammonium" (and no UV-C light) arm will be considered the reference group.
Time on Diversion	Each study period (6 months)	Hospital data will be gathered to determine if use of UV-C emitting devices leads to downstream effects on hospital process. The proportion will be calculated as the average number of days on diversion per month for each study period. This proportion will be calculated for each study arm, each of which lasts 6 months. The "quaternary ammonium" (and no UV-C light) will be considered the reference group.
Incidence rate of healthcare-associated infections caused by target vegetative bacteria (MRSA, VRE, MDR-Acinetobacter) among all hospitalized patients.	Patients will be followed an average of 30 days	Patients will be monitored for HAIs due to MRSA, VRE, and MDR-Acinetobacter regardless of exposure to seed room. NHSN definitions for HAIs will be used.
Room Turnover Time	Each study period (6 months)	Room cleaning process will be monitored and tracked. We will obtain start and stop times for terminal room cleaning to determine if use of UV-C light emitting devices leads to additional time for room turnover. Average times will be calculated for each study arm, each of which lasts 6 months. The "quaternary ammonium" (and no UV-C light) arm will be considered the reference group.
ED to floor wait time	Each study period (6 months)	Hospital data will be gathered to determine if use of UV-C emitting devices leads to downstream effects on hospital process. Average times will be calculated for each study arm, each of which lasts 6 months. The "quaternary ammonium" (and no UV-C light) arm will be considered the reference group.
Clinical incidence of MRSA, VRE, C. difficile, and MDR-Acinetobacter during UV-C light versus No UV-C light	12 months (2 6-month study arms combined)	The clinical incidence rate of MRSA, VRE, C. difficile, and MDR-Acinetobacter will be calculated for the two 6-month study arms (12 months total) during which UV-C light is used for terminal room disinfection (regardless of which chemical is used) and compared to the two 6-month study arms (12 months total) during which UV-C light is not used for terminal room disinfection.

Trial Locations

Locations (9)

Duke Raleigh Hospital; 🇺🇸 Raleigh, North Carolina, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States

Alamance Regional Medical Center; 🇺🇸 Burlington, North Carolina, United States

Durham Regional Hospital; 🇺🇸 Durham, North Carolina, United States

Durham VA Medical Center; 🇺🇸 Durham, North Carolina, United States

Chesapeake Regional Medical Center; 🇺🇸 Chesapeake, Virginia, United States

High Point Regional Health System; 🇺🇸 High Point, North Carolina, United States

Rex Healthcare; 🇺🇸 Raleigh, North Carolina, United States

University of North Carolina Hospitals; 🇺🇸 Chapel Hill, North Carolina, United States